Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ilda Costa
Clinical Insights Gained by Refining the 2016 WHO Classification of Diffuse Gliomas With: EGFR Amplification, TERT Mutations, PTEN Deletion and MGMT Methylation
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
CAMKK2, Regulated by Promoter Methylation, Is a Prognostic Marker in Diffuse Gliomas
CNS Neuroscience and Therapeutics
Psychiatry
Mental Health
Physiology
Pharmacology
A Novel Analytical Model of MGMT Methylation Pyrosequencing Offers Improved Predictive Performance in Patients With Gliomas
Modern Pathology
Forensic Medicine
Pathology
Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors
Journal of Molecular Diagnostics
Forensic Medicine
Pathology
Molecular Medicine
Prognostic or Predictive Value of MGMT Promoter Methylation in Gliomas Depends on IDH1 Mutation
Neurology
Neurology
TERT Promoter Mutations and Telomere Length in Adult Malignant Gliomas and Recurrences
Oncotarget
Oncology
Interplay Between TERT Promoter Mutations and Methylation Culminates in Chromatin Accessibility and TERT Expression
PTEN/MMAC1 Mutations in Primary Glioblastomas and Short-Term Cultures of Malignant Gliomas
Oncogene
Cancer Research
Genetics
Molecular Biology
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Cancer Cell
Cancer Research
Oncology
Cell Biology
The Clinical Implications of Inconsistently Methylated Results From Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR
Journal of Molecular Diagnostics
Forensic Medicine
Pathology
Molecular Medicine
